New England Asset Management Inc. raised its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 20.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,920 shares of the medical instruments supplier's stock after purchasing an additional 4,705 shares during the period. New England Asset Management Inc.'s holdings in Becton, Dickinson and Company were worth $6,395,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Nissay Asset Management Corp Japan ADV raised its stake in shares of Becton, Dickinson and Company by 1.5% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 36,643 shares of the medical instruments supplier's stock valued at $8,393,000 after buying an additional 529 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 5.5% in the 1st quarter. NewEdge Advisors LLC now owns 17,443 shares of the medical instruments supplier's stock valued at $3,995,000 after buying an additional 904 shares in the last quarter. Nippon Life Global Investors Americas Inc. raised its stake in shares of Becton, Dickinson and Company by 16.7% in the 1st quarter. Nippon Life Global Investors Americas Inc. now owns 45,560 shares of the medical instruments supplier's stock valued at $10,436,000 after buying an additional 6,530 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Becton, Dickinson and Company by 8.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,735 shares of the medical instruments supplier's stock valued at $5,895,000 after buying an additional 2,034 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its stake in shares of Becton, Dickinson and Company by 7.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 5,323 shares of the medical instruments supplier's stock valued at $1,219,000 after buying an additional 350 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Activity at Becton, Dickinson and Company
In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Claire Fraser sold 863 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the sale, the director owned 23,143 shares of the company's stock, valued at approximately $4,450,398.90. This represents a 3.59% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.
Becton, Dickinson and Company Price Performance
BDX traded up $1.57 during midday trading on Thursday, hitting $190.00. The company had a trading volume of 509,814 shares, compared to its average volume of 2,579,471. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $54.46 billion, a PE ratio of 34.13, a P/E/G ratio of 1.42 and a beta of 0.27. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm's 50-day simple moving average is $185.95 and its 200-day simple moving average is $192.31.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 74.82%.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on BDX shares. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Piper Sandler reissued a "neutral" rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Barclays cut their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Finally, Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $211.44.
View Our Latest Research Report on Becton, Dickinson and Company
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
